<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;v=2.18.0.post9+e462414&amp;utm_source=Chrome&amp;ff=20241029001351&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;v=2.18.0.post9+e462414&amp;utm_source=Chrome&amp;ff=20241029001351&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Tue, 29 Oct 2024 04:13:52 +0000</lastbuilddate>
<pubDate>Mon, 28 Oct 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Well-Conducted Real-World Evidence Studies Can Complement Essential Evidence From Clinical Trials</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39466890/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241029001351&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 29;150(18):1412-1415. doi: 10.1161/CIRCULATIONAHA.124.069220. Epub 2024 Oct 28.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39466890/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241029001351&v=2.18.0.post9+e462414">39466890</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069220>10.1161/CIRCULATIONAHA.124.069220</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39466890</guid>
<pubDate>Mon, 28 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Elisabetta Patorno</dc:creator>
<dc:date>2024-10-28</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Well-Conducted Real-World Evidence Studies Can Complement Essential Evidence From Clinical Trials</dc:title>
<dc:identifier>pmid:39466890</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069220</dc:identifier>
</item>
<item>
<title>Mixed Cardiogenic Shock: A Proposal for Standardized Classification, a Hemodynamic Definition, and Framework for Management</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39466889/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241029001351&amp;v=2.18.0.post9+e462414
      <description>The classification of cardiogenic shock (CS) has evolved from a singular cold-and wet-hemodynamic profile. Data from registries and clinical trials have contributed to a broader recognition that although all patients with CS have insufficient cardiac output leading to end organ hypoperfusion, there is considerable variability in CS acuity, underlying etiologies, volume status, and systemic vascular resistance. Mixed CS can be broadly categorized as CS with at least 1 additional shock state....</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 29;150(18):1459-1468. doi: 10.1161/CIRCULATIONAHA.124.069508. Epub 2024 Oct 28.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The classification of cardiogenic shock (CS) has evolved from a singular cold-and wet-hemodynamic profile. Data from registries and clinical trials have contributed to a broader recognition that although all patients with CS have insufficient cardiac output leading to end organ hypoperfusion, there is considerable variability in CS acuity, underlying etiologies, volume status, and systemic vascular resistance. Mixed CS can be broadly categorized as <i>CS with at least 1 additional shock state</i>. Mixed CS states are now the second leading cause of shock in contemporary coronary intensive care units, but there is little high-quality evidence to guide routine care, and there are no standardized classification frameworks or well-established hemodynamic definitions. This primer summarizes the current epidemiology and proposes a classification framework and invasive hemodynamic parameters to guide categorization that could be applied to help better phenotype patients captured in registries and trials, as well as guide management of mixed CS states.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39466889/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241029001351&v=2.18.0.post9+e462414">39466889</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069508>10.1161/CIRCULATIONAHA.124.069508</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39466889</guid>
<pubDate>Mon, 28 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Sean van Diepen</dc:creator>
<dc:creator>Janine Pöss</dc:creator>
<dc:creator>Janek M Senaratne</dc:creator>
<dc:creator>Ann Gage</dc:creator>
<dc:creator>David A Morrow</dc:creator>
<dc:date>2024-10-28</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Mixed Cardiogenic Shock: A Proposal for Standardized Classification, a Hemodynamic Definition, and Framework for Management</dc:title>
<dc:identifier>pmid:39466889</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069508</dc:identifier>
</item>
<item>
<title>Centennial Collection: Hypertrophic Cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39466888/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241029001351&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 29;150(18):1395-1397. doi: 10.1161/CIRCULATIONAHA.124.070134. Epub 2024 Oct 28.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39466888/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241029001351&v=2.18.0.post9+e462414">39466888</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070134>10.1161/CIRCULATIONAHA.124.070134</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39466888</guid>
<pubDate>Mon, 28 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Sharlene M Day</dc:creator>
<dc:date>2024-10-28</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Centennial Collection: Hypertrophic Cardiomyopathy</dc:title>
<dc:identifier>pmid:39466888</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070134</dc:identifier>
</item>
<item>
<title>A Rhythm Hidden in the Details</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39466887/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241029001351&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 29;150(18):1475-1477. doi: 10.1161/CIRCULATIONAHA.124.072049. Epub 2024 Oct 28.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39466887/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241029001351&v=2.18.0.post9+e462414">39466887</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072049>10.1161/CIRCULATIONAHA.124.072049</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39466887</guid>
<pubDate>Mon, 28 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Shasha Yu</dc:creator>
<dc:creator>Jingyu Jiao</dc:creator>
<dc:creator>Ming Liu</dc:creator>
<dc:date>2024-10-28</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>A Rhythm Hidden in the Details</dc:title>
<dc:identifier>pmid:39466887</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072049</dc:identifier>
</item>
<item>
<title>Oral Anticoagulation in Device Patients With Atrial High-Rate Episodes: Shared Decision-Making After ARTESIA and NOAH-AFNET-6</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39466886/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241029001351&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 29;150(18):1398-1400. doi: 10.1161/CIRCULATIONAHA.124.068018. Epub 2024 Oct 28.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39466886/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241029001351&v=2.18.0.post9+e462414">39466886</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.068018>10.1161/CIRCULATIONAHA.124.068018</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39466886</guid>
<pubDate>Mon, 28 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Christine M Albert</dc:creator>
<dc:date>2024-10-28</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Oral Anticoagulation in Device Patients With Atrial High-Rate Episodes: Shared Decision-Making After ARTESIA and NOAH-AFNET-6</dc:title>
<dc:identifier>pmid:39466886</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.068018</dc:identifier>
</item>
<item>
<title>Highlights From the Circulation Family of Journals</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39466885/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241029001351&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 29;150(18):1469-1474. doi: 10.1161/CIRCULATIONAHA.124.072348. Epub 2024 Oct 28.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39466885/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241029001351&v=2.18.0.post9+e462414">39466885</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072348>10.1161/CIRCULATIONAHA.124.072348</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39466885</guid>
<pubDate>Mon, 28 Oct 2024 06:00:00 -0400</pubDate>
<dc:date>2024-10-28</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Highlights From the Circulation Family of Journals</dc:title>
<dc:identifier>pmid:39466885</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072348</dc:identifier>
</item>
<item>
<title>Prevalence of Coronary Atherosclerosis in Female Masters Endurance Athletes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39466884/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241029001351&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 29;150(18):1478-1480. doi: 10.1161/CIRCULATIONAHA.124.069484. Epub 2024 Oct 28.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39466884/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241029001351&v=2.18.0.post9+e462414">39466884</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069484>10.1161/CIRCULATIONAHA.124.069484</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39466884</guid>
<pubDate>Mon, 28 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Efstathios Papatheodorou</dc:creator>
<dc:creator>Vincent L Aengevaeren</dc:creator>
<dc:creator>Thijs M H Eijsvogels</dc:creator>
<dc:creator>Khaled AlFakih</dc:creator>
<dc:creator>Rebecca Kathryn Hughes</dc:creator>
<dc:creator>Ahmed Merghani</dc:creator>
<dc:creator>Christine K Kissel</dc:creator>
<dc:creator>Saad Fyyaz</dc:creator>
<dc:creator>Athanasios Bakalakos</dc:creator>
<dc:creator>Mathew G Wilson</dc:creator>
<dc:creator>Damini Dey</dc:creator>
<dc:creator>Gherardo Finocchiaro</dc:creator>
<dc:creator>Gemma Parry-Williams</dc:creator>
<dc:creator>Camilla Torlasco</dc:creator>
<dc:creator>Michael Papadakis</dc:creator>
<dc:creator>James C Moon</dc:creator>
<dc:creator>Sanjay Sharma</dc:creator>
<dc:date>2024-10-28</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Prevalence of Coronary Atherosclerosis in Female Masters Endurance Athletes</dc:title>
<dc:identifier>pmid:39466884</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069484</dc:identifier>
</item>
<item>
<title>Diagnostic Performance and Clinical Impact of Photon-Counting Detector Computed Tomography in Coronary Artery Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39466216/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241029001351&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: PCD-CT exhibited excellent diagnostic performance for detecting obstructive CAD. Compared with patients undergoing conventional EID-CT, fewer patients were referred to ICA after PCD-CT, but those referred were more likely to undergo revascularization.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 23:S0735-1097(24)09956-X. doi: 10.1016/j.jacc.2024.10.069. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Photon-counting detector-computed tomography (PCD-CT) has emerged as a promising technology, offering improved spatial resolution.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study aimed to evaluate the clinical impact and diagnostic performance of PCD-CT vs conventional energy-integrating detector computed tomography (EID-CT) for obstructive coronary artery disease (CAD).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: From 2022 to 2023, we retrospectively identified 7,833 consecutive patients who underwent clinically indicated coronary computed tomography angiography (CCTA) at a single center, with either PCD-CT (n = 3,876; NAEOTOM Alpha [Siemens Healthineers]) or EID-CT (n = 3,957; Revolution Apex 256 [GE HealthCare] or Aquilion ONE ViSION 320 [Canon Medical Systems]) scanners. Subsequent invasive coronary angiography (ICA) and percutaneous or surgical revascularization were performed as part of routine clinical care. Among those referred for ICA after coronary CTA, the presence of obstructive CAD in each vessel was determined by coronary CTA (severe stenosis on visual assessment per the Coronary Artery Disease Reporting and Data System) and ICA (≥50% diameter stenosis on quantitative coronary angiography) in a blinded fashion. The diagnostic performance of EID-CT and PCD-CT was compared by using quantitative coronary angiography as the reference standard.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Patients who underwent PCD-CT were less frequently referred to subsequent ICA than those undergoing EID-CT (9.9% vs 13.1%; P &lt; 0.001). Among those who underwent ICA, revascularization was more frequently performed in the PCD-CT group than in the EID-CT group (43.4% vs 35.5%; P = 0.02). In the vessel-level analysis (n = 1,686), specificity (98.0% vs 93.0%; P &lt; 0.001), positive predictive value (83.3% vs 63.0%; P = 0.002), and diagnostic accuracy (97.2% vs 92.8%; P &lt; 0.001) were improved by PCD-CT. Sensitivity (90.9% vs 90.7%; P = 0.95) and negative predictive value (98.9% vs 98.7%; P = 0.83) for obstructive CAD were similar between the PCD-CT and EID-CT groups, respectively.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: PCD-CT exhibited excellent diagnostic performance for detecting obstructive CAD. Compared with patients undergoing conventional EID-CT, fewer patients were referred to ICA after PCD-CT, but those referred were more likely to undergo revascularization.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39466216/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241029001351&v=2.18.0.post9+e462414">39466216</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.069>10.1016/j.jacc.2024.10.069</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39466216</guid>
<pubDate>Mon, 28 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Koshiro Sakai</dc:creator>
<dc:creator>Doosup Shin</dc:creator>
<dc:creator>Mandeep Singh</dc:creator>
<dc:creator>Sarah Malik</dc:creator>
<dc:creator>Ali Dakroub</dc:creator>
<dc:creator>Zainab Sami</dc:creator>
<dc:creator>Jonathan Weber</dc:creator>
<dc:creator>J Jane Cao</dc:creator>
<dc:creator>Roosha Parikh</dc:creator>
<dc:creator>Lu Chen</dc:creator>
<dc:creator>Fernando Sosa</dc:creator>
<dc:creator>David J Cohen</dc:creator>
<dc:creator>Jeffrey W Moses</dc:creator>
<dc:creator>Richard A Shlofmitz</dc:creator>
<dc:creator>Carlos Collet</dc:creator>
<dc:creator>Evan Shlofmitz</dc:creator>
<dc:creator>Allen Jeremias</dc:creator>
<dc:creator>Omar K Khalique</dc:creator>
<dc:creator>Ziad A Ali</dc:creator>
<dc:date>2024-10-28</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Diagnostic Performance and Clinical Impact of Photon-Counting Detector Computed Tomography in Coronary Artery Disease</dc:title>
<dc:identifier>pmid:39466216</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.069</dc:identifier>
</item>
<item>
<title>Transcatheter Valve Repair for Tricuspid Regurgitation: 1-Year Results from a Large European Real-World Registry</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39466215/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241029001351&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The PASCAL system effectively treats severe TR in high-risk patients, offering sustained TR reduction and significant clinical improvements at 1-year follow-up. (PASCAL for Tricuspid Regurgitation-a European registry [PASTE]; NCT05328284).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 24:S0735-1097(24)09955-8. doi: 10.1016/j.jacc.2024.10.068. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Tricuspid valve transcatheter edge-to-edge repair has emerged as a valuable treatment option for patients with severe tricuspid regurgitation (TR).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study aims to investigate the safety and effectiveness of the PASCAL transcatheter valve repair system in treating severe TR in a real-world patient population.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The PASTE (PASCAL for Tricuspid Regurgitation-a European registry) study is an investigator-initiated, multicenter, retrospective, and prospective observational cohort analysis conducted across 16 European heart valve centers including consecutive patients treated with the PASCAL transcatheter valve repair system from February 2019 to November 2023. Echocardiographic assessments were performed at baseline, discharge, and follow-up, and were subjected to centralized analysis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The study included 1,059 high-risk patients (mean age 79 ± 9 years; 53% female; TRI-SCORE risk 23% ± 18%; 87% NYHA functional class III/IV) with multiple comorbidities. Severe or higher graded TR was observed in 96% of patients. Intraprocedural success according to Tricuspid Valve Academic Research Consortium criteria was achieved in 85%, and TR reduced to ≤moderate in 87%. Independent predictors for a postprocedure residual TR of >;moderate were coaptation gaps ≥8 mm (OR: 1.67; 95% CI: 1.03-2.72; P = 0.038), tenting height ≥10 mm (OR: 2.18; CI: 1.30-3.65; P = 0.003), the presence of a transvalvular lead (OR: 1.91; 95% CI: 1.19-3.05; P = 0.007), right ventricular dilatation >;42 mm (OR: 3.35; 95% CI: 1.37-9.1; P = 0.009) and massive/torrential TR at baseline (OR: 4.59; 95% CI: 2.35-8.96; P &lt; 0.001). At 1 year, 83% of patients showed ≤moderate TR. Significant clinical improvements included enhanced NYHA functional class (66% class I/II vs 17% at baseline; P &lt; 0.001). Patients treated with the first-generation PASCAL system (n = 570) and with the new PASCAL Precision system (n = 489) had similar clinical profiles and TR severity at baseline. However, the Precision cohort showed greater TR reduction to trace/mild (63% vs 49%; P &lt; 0.001), shorter procedure times (median 93 minutes [Q1-Q3: 69-130 minutes] vs 120 minutes [Q1-Q3: 82-165 minutes]; P &lt; 0.001), and higher clinical success rates according to the Tricuspid Valve Academic Research Consortium at 30 days and 1 year (87% vs 81% [P = 0.021] and 56% vs 50% [P = 0.044], respectively). Higher center experience (≥21 patients/year) resulted in higher intraprocedural and clinical success.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The PASCAL system effectively treats severe TR in high-risk patients, offering sustained TR reduction and significant clinical improvements at 1-year follow-up. (PASCAL for Tricuspid Regurgitation-a European registry [PASTE]; NCT05328284).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39466215/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241029001351&v=2.18.0.post9+e462414">39466215</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.068>10.1016/j.jacc.2024.10.068</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39466215</guid>
<pubDate>Mon, 28 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Mirjam G Wild</dc:creator>
<dc:creator>Lukas Stolz</dc:creator>
<dc:creator>Sebastian Rosch</dc:creator>
<dc:creator>Felix Rudolph</dc:creator>
<dc:creator>Björn Goebel</dc:creator>
<dc:creator>Benedikt Köll</dc:creator>
<dc:creator>Philipp von Stein</dc:creator>
<dc:creator>Wolfgang Rottbauer</dc:creator>
<dc:creator>Tienush Rassaf</dc:creator>
<dc:creator>Harald Beucher</dc:creator>
<dc:creator>Martin Kraus</dc:creator>
<dc:creator>Mohammad Kassar</dc:creator>
<dc:creator>Tobias Geisler</dc:creator>
<dc:creator>Andreas Rück</dc:creator>
<dc:creator>Joao Ferreira-Martins</dc:creator>
<dc:creator>Stefan Toggweiler</dc:creator>
<dc:creator>Paula Sagmeister</dc:creator>
<dc:creator>Dirk Westermann</dc:creator>
<dc:creator>Thomas J Stocker</dc:creator>
<dc:creator>Ludwig T Weckbach</dc:creator>
<dc:creator>Michael Näbauer</dc:creator>
<dc:creator>Magnus Settergren</dc:creator>
<dc:creator>Sam Dawkins</dc:creator>
<dc:creator>Tobias Kister</dc:creator>
<dc:creator>Fabien Praz</dc:creator>
<dc:creator>Marc Vorpahl</dc:creator>
<dc:creator>Mathias H Konstandin</dc:creator>
<dc:creator>Peter Lüdike</dc:creator>
<dc:creator>Mirjam Keßler</dc:creator>
<dc:creator>Christos Iliadis</dc:creator>
<dc:creator>Daniel Kalbacher</dc:creator>
<dc:creator>Philip Lauten</dc:creator>
<dc:creator>Muhammed Gerçek</dc:creator>
<dc:creator>Christian Besler</dc:creator>
<dc:creator>Philipp Lurz</dc:creator>
<dc:creator>Jörg Hausleiter</dc:creator>
<dc:creator>PASTE Investigators</dc:creator>
<dc:date>2024-10-28</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Transcatheter Valve Repair for Tricuspid Regurgitation: 1-Year Results from a Large European Real-World Registry</dc:title>
<dc:identifier>pmid:39466215</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.068</dc:identifier>
</item>
<item>
<title>CAR-Macrophage Therapy Alleviates Myocardial Ischemia-Reperfusion Injury</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39465245/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241029001351&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our proof-of-concept study demonstrates the therapeutic potential of FAP CAR-Ms in alleviating myocardial I/R and potentially opens new avenues for the treatment of a range of heart diseases that include a fibrotic phenotype.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Oct 28. doi: 10.1161/CIRCRESAHA.124.325212. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Given the growing acknowledgment of the detrimental effects of excessive myocardial fibrosis on pathological remodeling after myocardial ischemia-reperfusion injury (I/R), targeting the modulation of myocardial fibrosis may offer protective and therapeutic advantages. However, effective clinical interventions and therapies that target myocardial fibrosis remain limited. As a promising chimeric antigen receptor (CAR) cell therapy, whether CAR macrophages (CAR-Ms) can be used to treat I/R remains unclear.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The expression of FAP (fibroblast activation protein) was studied in mouse hearts after I/R. FAP CAR-Ms were generated to target FAP-expressing cardiac fibroblasts in mouse hearts after I/R. The phagocytosis activity of FAP CAR-Ms was tested in vitro. The efficacy and safety of FAP CAR-Ms in treating I/R were evaluated in vivo.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: FAP was significantly upregulated in activated cardiac fibroblasts as early as 3 days after I/R. Upon demonstrating their ability to engulf FAP-overexpressing fibroblasts, we intravenously administered FAP CAR-Ms to mice at 3 days after I/R and found that FAP CAR-Ms significantly improved cardiac function and reduced myocardial fibrosis in mice after I/R. No toxicities associated with FAP CAR-Ms were detected in the heart or other organs at 2 weeks after I/R. Finally, we found that FAP CAR-Ms conferred long-term cardioprotection against I/R.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our proof-of-concept study demonstrates the therapeutic potential of FAP CAR-Ms in alleviating myocardial I/R and potentially opens new avenues for the treatment of a range of heart diseases that include a fibrotic phenotype.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39465245/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241029001351&v=2.18.0.post9+e462414">39465245</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325212>10.1161/CIRCRESAHA.124.325212</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39465245</guid>
<pubDate>Mon, 28 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Jiawan Wang</dc:creator>
<dc:creator>Heng Du</dc:creator>
<dc:creator>Wanrun Xie</dc:creator>
<dc:creator>Jinmiao Bi</dc:creator>
<dc:creator>Hao Zhang</dc:creator>
<dc:creator>Xu Liu</dc:creator>
<dc:creator>Yuhan Wang</dc:creator>
<dc:creator>Shaolong Zhang</dc:creator>
<dc:creator>Anhua Lei</dc:creator>
<dc:creator>Chuting He</dc:creator>
<dc:creator>Hailong Yuan</dc:creator>
<dc:creator>Jiahe Zhang</dc:creator>
<dc:creator>Yujing Li</dc:creator>
<dc:creator>Pengfei Xu</dc:creator>
<dc:creator>Siqi Liu</dc:creator>
<dc:creator>Yanan Zhou</dc:creator>
<dc:creator>Jianghua Shen</dc:creator>
<dc:creator>Jingdong Wu</dc:creator>
<dc:creator>Yihong Cai</dc:creator>
<dc:creator>Chaofan Yang</dc:creator>
<dc:creator>Zeya Li</dc:creator>
<dc:creator>Yingxin Liang</dc:creator>
<dc:creator>Yang Zhao</dc:creator>
<dc:creator>Jin Zhang</dc:creator>
<dc:creator>Moshi Song</dc:creator>
<dc:date>2024-10-28</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>CAR-Macrophage Therapy Alleviates Myocardial Ischemia-Reperfusion Injury</dc:title>
<dc:identifier>pmid:39465245</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325212</dc:identifier>
</item>
<item>
<title>Association Between Delay to First Shock and Successful First-Shock Ventricular Fibrillation Termination in Patients With Witnessed Out-of-Hospital Cardiac Arrest</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39462804/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241029001351&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Every minute of delay to first shock was associated with a significantly lower proportion of VF termination and return of organized rhythm. This may explain the worse outcomes in patients with a long delay to defibrillation. Reducing the time interval from emergency call to first shock to ≤6 minutes could be considered a key performance indicator of the chain of survival.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 27. doi: 10.1161/CIRCULATIONAHA.124.069834. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: In patients with out-of-hospital cardiac arrest who present with an initial shockable rhythm, a longer delay to the first shock decreases the probability of survival, often attributed to cerebral damage. The mechanisms of this decreased survival have not yet been elucidated. Estimating the probability of successful defibrillation and other factors in relation to the time to first shock may guide prehospital care systems to implement policies that improve patient survival by decreasing time to first shock.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Patients with a witnessed out-of-hospital cardiac arrest and ventricular fibrillation (VF) as an initial rhythm were included using the prospective ARREST registry (Amsterdam Resuscitation Studies). Patient and resuscitation data, including time-synchronized automated external defibrillator and manual defibrillator data, were analyzed to determine VF termination at 5 seconds after the first shock. Delay to first shock was defined as the time from initial emergency call until the first shock by any defibrillator. Outcomes were the proportion of VF termination, return of organized rhythm, transportation with return of spontaneous circulation, and survival to discharge, all in relation to the delay to first shock. A Poisson regression model with robust standard errors was used to estimate the association between delay to first shock and outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 3723 patients, the proportion of VF termination declined from 93% when the delay to first shock was &lt;6 minutes to 75% when that delay was >;16 minutes (<i>P</i><sub>trend</sub>&lt;0.001). Every additional minute in VF from emergency call was associated with 6% higher probability of failure to terminate VF (adjusted relative risk, 1.06 [95% CI, 1.04-1.07]), 4% lower probability of return of organized rhythm (adjusted relative risk, 0.96 [95% CI, 0.95-0.98]), and 6% lower probability of surviving to discharge (adjusted relative risk, 0.94 [95% CI, 0.93-0.95]).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Every minute of delay to first shock was associated with a significantly lower proportion of VF termination and return of organized rhythm. This may explain the worse outcomes in patients with a long delay to defibrillation. Reducing the time interval from emergency call to first shock to ≤6 minutes could be considered a key performance indicator of the chain of survival.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39462804/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241029001351&v=2.18.0.post9+e462414">39462804</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069834>10.1161/CIRCULATIONAHA.124.069834</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39462804</guid>
<pubDate>Mon, 28 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Remy Stieglis</dc:creator>
<dc:creator>Bas J Verkaik</dc:creator>
<dc:creator>Hanno L Tan</dc:creator>
<dc:creator>Rudolph W Koster</dc:creator>
<dc:creator>Hans van Schuppen</dc:creator>
<dc:creator>Christian van der Werf</dc:creator>
<dc:date>2024-10-28</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Association Between Delay to First Shock and Successful First-Shock Ventricular Fibrillation Termination in Patients With Witnessed Out-of-Hospital Cardiac Arrest</dc:title>
<dc:identifier>pmid:39462804</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069834</dc:identifier>
</item>
<item>
<title>Derivation and Validation of the PRECISE-HBR Score to Predict Bleeding After Percutaneous Coronary Intervention</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39462482/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241029001351&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The PRECISE-HBR score is a contemporary, simple 7-item risk score to predict bleeding after PCI, offering a moderate improvement in discrimination over multiple existing scores. Further evaluation is required to assess its impact on clinical practice.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 27. doi: 10.1161/CIRCULATIONAHA.124.072009. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Accurate bleeding risk stratification after percutaneous coronary intervention (PCI) is important for treatment individualization. However, there is still an unmet need for a more precise and standardized identification of high bleeding risk patients. We derived and validated a novel bleeding risk score by augmenting the PRECISE-DAPT score with the Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The derivation cohort comprised 29,188 patients undergoing PCI, of whom 1136 (3.9%) had a Bleeding Academic Research Consortium (BARC) 3 or 5 bleeding at 1 year, from four contemporary real-world registries and the XIENCE V USA trial. The PRECISE-DAPT score was refitted with a Fine-Gray model in the derivation cohort and extended with the ARC-HBR criteria. The primary outcome was BARC 3 or 5 bleeding within 1 year. Independent predictors of BARC 3 or 5 bleeding were selected at multivariable analysis (p&lt;0.01). The discrimination of the score was internally assessed with apparent validation and cross-validation. The score was externally validated in 4578 patients from the MASTER DAPT trial and 5970 patients from the STOPDAPT-2 total cohort.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The PRECISE-HBR score (age, estimated glomerular filtration rate, hemoglobin, white-blood-cell count, previous bleeding, oral anticoagulation, and ARC-HBR criteria) showed an area under the curve (AUC) for 1-year BARC 3 or 5 bleeding of 0.73 (95% CI, 0.71-0.74) at apparent validation, 0.72 (95% CI, 0.70-0.73) at cross-validation, 0.74 (95% CI, 0.68-0.80) in the MASTER DAPT, and 0.73 (95% CI, 0.66-0.79) in the STOPDAPT-2, with superior discrimination than the PRECISE-DAPT (cross-validation: Δ AUC, 0.01; p=0.02; MASTER DAPT: Δ AUC, 0.05; p=0.004; STOPDAPT-2: Δ AUC, 0.02; p=0.20) and other risk scores. In the derivation cohort, a cut-off of 23 points identified 11,414 patients (39.1%) with a 1-year BARC 3 or 5 bleeding risk ≥4%. An alternative version of the score, including acute myocardial infarction on admission instead of white-blood-cell count, showed similar predictive ability.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The PRECISE-HBR score is a contemporary, simple 7-item risk score to predict bleeding after PCI, offering a moderate improvement in discrimination over multiple existing scores. Further evaluation is required to assess its impact on clinical practice.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39462482/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241029001351&v=2.18.0.post9+e462414">39462482</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072009>10.1161/CIRCULATIONAHA.124.072009</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39462482</guid>
<pubDate>Sun, 27 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Felice Gragnano</dc:creator>
<dc:creator>David van Klaveren</dc:creator>
<dc:creator>Dik Heg</dc:creator>
<dc:creator>Lorenz Räber</dc:creator>
<dc:creator>Mitchell W Krucoff</dc:creator>
<dc:creator>Sergio Raposeiras-Roubän</dc:creator>
<dc:creator>Jurriën M Ten Berg</dc:creator>
<dc:creator>Sergio Leonardi</dc:creator>
<dc:creator>Takeshi Kimura</dc:creator>
<dc:creator>Noé Corpataux</dc:creator>
<dc:creator>Alessandro Spirito</dc:creator>
<dc:creator>James B Hermiller</dc:creator>
<dc:creator>Emad Abu-Assi</dc:creator>
<dc:creator>Dean Chan Pin Yin</dc:creator>
<dc:creator>Jaouad Azzahhafi</dc:creator>
<dc:creator>Claudio Montalto</dc:creator>
<dc:creator>Marco Galazzi</dc:creator>
<dc:creator>Sarah Bär</dc:creator>
<dc:creator>Raminta Kavaliauskaite</dc:creator>
<dc:creator>Fabrizio D'Ascenzo</dc:creator>
<dc:creator>Gaetano M De Ferrari</dc:creator>
<dc:creator>Hirotoshi Watanabe</dc:creator>
<dc:creator>Philippe Gabriel Steg</dc:creator>
<dc:creator>Deepak L Bhatt</dc:creator>
<dc:creator>Paolo Calabrò</dc:creator>
<dc:creator>Roxana Mehran</dc:creator>
<dc:creator>Philip Urban</dc:creator>
<dc:creator>Stuart Pocock</dc:creator>
<dc:creator>Stephan Windecker</dc:creator>
<dc:creator>Marco Valgimigli</dc:creator>
<dc:date>2024-10-27</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Derivation and Validation of the PRECISE-HBR Score to Predict Bleeding After Percutaneous Coronary Intervention</dc:title>
<dc:identifier>pmid:39462482</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072009</dc:identifier>
</item>
<item>
<title>Fractional Flow Reserve and Instantaneous Wave-Free Ratio as Predictors of the Placebo-Controlled Response to Percutaneous Coronary Intervention in Stable Coronary Artery Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39462291/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241029001351&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Physiological stenosis severity, as measured by FFR and iFR, predicts placebo-controlled angina relief from PCI. Invasive coronary physiology can be used to target PCI to those patients who are most likely to experience benefit.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 27. doi: 10.1161/CIRCULATIONAHA.124.072281. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The Placebo-controlled Trial of Percutaneous Coronary Intervention for the Relief of Stable Angina (ORBITA-2) provided evidence for the role of percutaneous coronary intervention (PCI) for angina relief in stable coronary artery disease (CAD). Fractional flow reserve (FFR) and instantaneous wave-free ratio (iFR) are often used to guide PCI, however their ability to predict placebo-controlled angina improvement is unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Participants with angina, ischemia, and stable CAD were enrolled and antianginal medications were stopped. Participants reported angina episodes daily for 2 weeks using the ORBITA-app. At the research angiogram, FFR and iFR were measured. After sedation and auditory isolation, participants were randomized to PCI or placebo, before entering a 12-week blinded follow-up phase with daily angina reporting. The ability of FFR and iFR, analyzed as continuous variables, to predict the placebo-controlled effect of PCI, was tested using Bayesian proportional odds modelling.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Invasive physiology data were available in 279 patients (140 PCI and 139 placebo). The median (IQR) age was 65 years (59.0 to 70.5) and 223 (79.9%) were male. Median FFR was 0.60 (0.46 to 0.73) and median iFR was 0.76 (0.50 to 0.86). The lower the FFR or iFR, the greater the placebo-controlled improvement with PCI across all endpoints. There was strong evidence that a patient with an FFR at the lower quartile would have a greater placebo-controlled improvement in angina symptom score with PCI than a patient at the upper quartile (FFR 0.46 vs. 0.73: OR 2.01, 95% CrI 1.79 to 2.26, Pr(Interaction)>;99.9%). Similarly, there was strong evidence that a patient with an iFR at the lower quartile would have a greater placebo controlled improvement in angina symptom score with PCI than a patient with an iFR at the upper quartile (iFR 0.50 vs. 0.86: OR 2.13, 95% CrI 1.87 to 2.45, Pr(Interaction) >;99.9%). The relationship between benefit and physiology was seen in both Rose angina and Rose nonangina.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Physiological stenosis severity, as measured by FFR and iFR, predicts placebo-controlled angina relief from PCI. Invasive coronary physiology can be used to target PCI to those patients who are most likely to experience benefit.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39462291/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241029001351&v=2.18.0.post9+e462414">39462291</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072281>10.1161/CIRCULATIONAHA.124.072281</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39462291</guid>
<pubDate>Sun, 27 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Michael J Foley</dc:creator>
<dc:creator>Christopher A Rajkumar</dc:creator>
<dc:creator>Fiyyaz Ahmed-Jushuf</dc:creator>
<dc:creator>Florentina Simader</dc:creator>
<dc:creator>Shayna Chotai</dc:creator>
<dc:creator>Henry Seligman</dc:creator>
<dc:creator>Krzysztof Macierzanka</dc:creator>
<dc:creator>John R Davies</dc:creator>
<dc:creator>Thomas R Keeble</dc:creator>
<dc:creator>Peter O'Kane</dc:creator>
<dc:creator>Peter Haworth</dc:creator>
<dc:creator>Helen Routledge</dc:creator>
<dc:creator>Tushar Kotecha</dc:creator>
<dc:creator>Gerald Clesham</dc:creator>
<dc:creator>Rupert Williams</dc:creator>
<dc:creator>Jehangir Din</dc:creator>
<dc:creator>Sukhjinder S Nijjer</dc:creator>
<dc:creator>Nick Curzen</dc:creator>
<dc:creator>Manas Sinha</dc:creator>
<dc:creator>Ricardo Petraco</dc:creator>
<dc:creator>James Spratt</dc:creator>
<dc:creator>Sayan Sen</dc:creator>
<dc:creator>Graham D Cole</dc:creator>
<dc:creator>Frank E Harrell</dc:creator>
<dc:creator>James P Howard</dc:creator>
<dc:creator>Darrel P Francis</dc:creator>
<dc:creator>Matthew J Shun-Shin</dc:creator>
<dc:creator>Rasha Al-Lamee</dc:creator>
<dc:creator>ORBITA-2 investigators</dc:creator>
<dc:date>2024-10-27</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Fractional Flow Reserve and Instantaneous Wave-Free Ratio as Predictors of the Placebo-Controlled Response to Percutaneous Coronary Intervention in Stable Coronary Artery Disease</dc:title>
<dc:identifier>pmid:39462291</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072281</dc:identifier>
</item>
<item>
<title>In Which Patients Will PCI Relieve Angina?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39462289/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241029001351&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 27. doi: 10.1161/CIRCULATIONAHA.124.072466. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39462289/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241029001351&v=2.18.0.post9+e462414">39462289</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072466>10.1161/CIRCULATIONAHA.124.072466</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39462289</guid>
<pubDate>Sun, 27 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>William F Fearon</dc:creator>
<dc:date>2024-10-27</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>In Which Patients Will PCI Relieve Angina?</dc:title>
<dc:identifier>pmid:39462289</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072466</dc:identifier>
</item>
<item>
<title>End-Organ Injury and Failure: The True DanGer in Cardiogenic Shock</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39462278/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241029001351&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 27. doi: 10.1161/CIRCULATIONAHA.124.072571. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39462278/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241029001351&v=2.18.0.post9+e462414">39462278</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072571>10.1161/CIRCULATIONAHA.124.072571</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39462278</guid>
<pubDate>Sun, 27 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Saraschandra Vallabhajosyula</dc:creator>
<dc:date>2024-10-27</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>End-Organ Injury and Failure: The True DanGer in Cardiogenic Shock</dc:title>
<dc:identifier>pmid:39462278</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072571</dc:identifier>
</item>
<item>
<title>Microaxial Flow Pump Use and Renal Outcomes in Infarct-Related Cardiogenic Shock - a Secondary Analysis of the DanGer Shock Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39462276/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241029001351&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Shock severity, allocation to mAFP, and device-related complications were associated with an increased risk of AKI. AKI was generally associated with higher mortality, but the allocation to mAFP consistently led to lower mortality rates at 180 days irrespective of the occurrence of AKI with or without RRT initiation.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 27. doi: 10.1161/CIRCULATIONAHA.124.072370. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: In the Danish-German Cardiogenic Shock (DanGer Shock) trial, use of a microaxial flow pump (mAFP) in patients with ST-segment elevation myocardial infarction (STEMI)-related CS led to lower all-cause mortality but higher rates of renal replacement therapy (RRT). In this prespecified analysis, rates and predictors of acute kidney injury (AKI) and RRT were assessed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In this international, randomized, open label, multicenter trial, 355 adult patients with STEMI-CS were randomized to mAFP (N=179) or standard care alone (N=176). AKI was defined according to Risk, Injury, and Failure, sustained Loss and End-stage kidney disease (RIFLE) criteria and assessed using logistic regression models. Use of RRT was assessed accounting for the competing risk of death using Fine-Gray subdistribution hazard models.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: AKI (RIFLE≥1) was recorded in 110 patients (61%) in mAFP group and 79 (45%) in control group (p&lt;0.01); RRT was used in 75 (42%) and 47 (27%) patients, respectively (p&lt;0.01). About 2/3 of the RRTs were initiated within the first 24h from admission (n=48 (64%) in mAFP group, n=31 (66%) in control group). Occurrence of AKI and RRT were associated with higher 180-day mortality in both study arms. At 180 days, all patients alive were free of RRT. mAFP use was associated with higher rates of RRT, even when accounting for competing risk of death (subdistribution hazard: 1.67 [1.18-2.35]). This association was largely consistent among prespecified subgroups. Allocation to mAFP was associated with lower 180-day mortality irrespective of AKI or RRT (p=0.8 for interaction). Relevant predictors of AKI in both groups comprised reduced left ventricular ejection fraction, baseline kidney function, shock severity, bleeding events, and positive fluid balance. In addition, predictors of AKI specific to mAFP were suction events, higher pump speed, and longer duration of support.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Shock severity, allocation to mAFP, and device-related complications were associated with an increased risk of AKI. AKI was generally associated with higher mortality, but the allocation to mAFP consistently led to lower mortality rates at 180 days irrespective of the occurrence of AKI with or without RRT initiation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39462276/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241029001351&v=2.18.0.post9+e462414">39462276</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072370>10.1161/CIRCULATIONAHA.124.072370</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39462276</guid>
<pubDate>Sun, 27 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Elric Zweck</dc:creator>
<dc:creator>Christian Hassager</dc:creator>
<dc:creator>Rasmus P Beske</dc:creator>
<dc:creator>Lisette O Jensen</dc:creator>
<dc:creator>Hans Eiskjær</dc:creator>
<dc:creator>Norman Mangner</dc:creator>
<dc:creator>Amin Polzin</dc:creator>
<dc:creator>P Christian Schulze</dc:creator>
<dc:creator>Carsten Skurk</dc:creator>
<dc:creator>Peter Nordbeck</dc:creator>
<dc:creator>Peter Clemmensen</dc:creator>
<dc:creator>Vasileios Panoulas</dc:creator>
<dc:creator>Sebastian Zimmer</dc:creator>
<dc:creator>Andreas Schäfer</dc:creator>
<dc:creator>Malte Kelm</dc:creator>
<dc:creator>Thomas Engstrøm</dc:creator>
<dc:creator>Lene Holmvang</dc:creator>
<dc:creator>Anders Junker</dc:creator>
<dc:creator>Henrik Schmidt</dc:creator>
<dc:creator>Christian J Terkelsen</dc:creator>
<dc:creator>Axel Linke</dc:creator>
<dc:creator>Ralf Westenfeld</dc:creator>
<dc:creator>Jacob E Møller</dc:creator>
<dc:creator>DanGer Shock Investigators</dc:creator>
<dc:date>2024-10-27</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Microaxial Flow Pump Use and Renal Outcomes in Infarct-Related Cardiogenic Shock - a Secondary Analysis of the DanGer Shock Trial</dc:title>
<dc:identifier>pmid:39462276</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072370</dc:identifier>
</item>
<item>
<title>Microaxial Flow Pump Hemodynamic and Metabolic Effects in Infarct-Related Cardiogenic Shock: A Substudy of the DanGer Shock Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39462240/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241029001351&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: Use of a MAFP reduces the use of vasopressors and inotropic medication while maintaining hemodynamic stability and achieving faster normalization of lactate level in patients with STEMI-CS.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Oct 27. doi: 10.1001/jamacardio.2024.4197. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Mechanical circulatory support with a microaxial flow pump (MAFP) has been shown to improve survival in ST-elevation myocardial infarction-induced cardiogenic shock (STEMI-CS). Understanding the impact on hemodynamic stability over time is crucial for optimizing patient treatment.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To determine if an MAFP reduces the need for pharmacological circulatory support without compromising hemodynamics compared with standard care in STEMI-CS.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This was a substudy of the Danish-German (DanGer) Shock trial, an international, multicenter, open-label randomized clinical trial. Patients from 14 heart centers across Denmark, Germany, and the UK were enrolled. Inclusion criteria for the trial were STEMI and systolic blood pressure less than 100 mm Hg or ongoing vasopressor treatment, left ventricular ejection fraction less than 45%, and arterial lactate level greater than 2.5 mmol/L. Of the enrolled patients, after exclusions from death in the catheterization laboratory or immediately on intensive care unit (ICU) admission, the remaining patients had serial recordings of hemodynamics, arterial lactate, and use of vasoactive drugs. Patients who were in comas after cardiac arrest and patients with mechanical complications or right ventricular failure were excluded. Data were analyzed from May to September 2024.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: MAFP and standard of care or standard of care alone.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Hemodynamic status in terms of heart rate and blood pressure, metabolic status in terms of arterial lactate concentration, and vasoactive-inotropic score (VIS). The clinical events during the first 72 hours were as follows: death from all causes, escalation of mechanical circulatory support, and discharge alive from the ICU.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: From 355 enrolled patients, 324 (mean [IQR] age, 68 [58-75] years; 259 male [80%]) underwent ICU treatment (169 [52%] in the MAFP group, 155 [48%] in the standard-care group). Baseline characteristics were balanced. There was no difference in heart rate between groups, and mean arterial pressure was above the treatment target of 65 mm Hg in both groups but was achieved with a lower VIS in the MAFP group. No difference in arterial lactate level was found between groups at randomization, but on arrival to the ICU, the MAFP group had significantly lower arterial lactate levels compared with the standard-care group (mean difference, 1.3 mmol/L; 95% CI, 0.7-1.9 mmol/L), a difference that persisted throughout the first 24 hours of observation. The MAFP group achieved lactate normalization (&lt;2 mmol/L) 12 hours (95% CI, 5-18 hours) before the standard-care group.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Use of a MAFP reduces the use of vasopressors and inotropic medication while maintaining hemodynamic stability and achieving faster normalization of lactate level in patients with STEMI-CS.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01633502.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39462240/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241029001351&v=2.18.0.post9+e462414">39462240</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4197>10.1001/jamacardio.2024.4197</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39462240</guid>
<pubDate>Sun, 27 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Nanna Louise Junker Udesen</dc:creator>
<dc:creator>Rasmus Paulin Beske</dc:creator>
<dc:creator>Christian Hassager</dc:creator>
<dc:creator>Lisette Okkels Jensen</dc:creator>
<dc:creator>Hans Eiskjær</dc:creator>
<dc:creator>Norman Mangner</dc:creator>
<dc:creator>Amin Polzin</dc:creator>
<dc:creator>P Christian Schulze</dc:creator>
<dc:creator>Carsten Skurk</dc:creator>
<dc:creator>Peter Nordbeck</dc:creator>
<dc:creator>Peter Clemmensen</dc:creator>
<dc:creator>Vasileios Panoulas</dc:creator>
<dc:creator>Sebastian Zimmer</dc:creator>
<dc:creator>Andreas Schäfer</dc:creator>
<dc:creator>Nikos Werner</dc:creator>
<dc:creator>Martin Frydland</dc:creator>
<dc:creator>Lene Holmvang</dc:creator>
<dc:creator>Jesper Kjærgaard</dc:creator>
<dc:creator>Thomas Engstøm</dc:creator>
<dc:creator>Henrik Schmidt</dc:creator>
<dc:creator>Anders Junker</dc:creator>
<dc:creator>Christian Juhl Terkelsen</dc:creator>
<dc:creator>Steffen Christensen</dc:creator>
<dc:creator>Axel Linke</dc:creator>
<dc:creator>Jacob Eifer Møller</dc:creator>
<dc:creator>DanGer Shock Investigators</dc:creator>
<dc:date>2024-10-27</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Microaxial Flow Pump Hemodynamic and Metabolic Effects in Infarct-Related Cardiogenic Shock: A Substudy of the DanGer Shock Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:39462240</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4197</dc:identifier>
</item>
<item>
<title>Evidence for Mechanical Circulatory Support in Cardiogenic Shock</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39462239/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241029001351&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Oct 27. doi: 10.1001/jamacardio.2024.4225. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39462239/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241029001351&v=2.18.0.post9+e462414">39462239</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4225>10.1001/jamacardio.2024.4225</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39462239</guid>
<pubDate>Sun, 27 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Jason E Bloom</dc:creator>
<dc:creator>Kais Hyasat</dc:creator>
<dc:creator>Ajay J Kirtane</dc:creator>
<dc:date>2024-10-27</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Evidence for Mechanical Circulatory Support in Cardiogenic Shock</dc:title>
<dc:identifier>pmid:39462239</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4225</dc:identifier>
</item>
<item>
<title>Streptococcus anginosus promotes gastric inflammation, atrophy, and tumorigenesis in mice</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39461336/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241029001351&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Oct 25:S0092-8674(24)01218-2. doi: 10.1016/j.cell.2024.10.036. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39461336/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241029001351&v=2.18.0.post9+e462414">39461336</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.036>10.1016/j.cell.2024.10.036</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39461336</guid>
<pubDate>Sat, 26 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Kaili Fu</dc:creator>
<dc:creator>Alvin Ho Kwan Cheung</dc:creator>
<dc:creator>Chi Chun Wong</dc:creator>
<dc:creator>Weixin Liu</dc:creator>
<dc:creator>Yunfei Zhou</dc:creator>
<dc:creator>Feixue Wang</dc:creator>
<dc:creator>Pingmei Huang</dc:creator>
<dc:creator>Kai Yuan</dc:creator>
<dc:creator>Olabisi Oluwabukola Coker</dc:creator>
<dc:creator>Yasi Pan</dc:creator>
<dc:creator>Danyu Chen</dc:creator>
<dc:creator>Nga Man Lam</dc:creator>
<dc:creator>Mengxue Gao</dc:creator>
<dc:creator>Xiang Zhang</dc:creator>
<dc:creator>He Huang</dc:creator>
<dc:creator>Ka Fai To</dc:creator>
<dc:creator>Joseph Jao Yiu Sung</dc:creator>
<dc:creator>Jun Yu</dc:creator>
<dc:date>2024-10-26</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Streptococcus anginosus promotes gastric inflammation, atrophy, and tumorigenesis in mice</dc:title>
<dc:identifier>pmid:39461336</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.036</dc:identifier>
</item>
<item>
<title>Environmental sustainability in cardiovascular practice: current challenges and future directions</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39455886/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241029001351&amp;v=2.18.0.post9+e462414
      <description>Cardiovascular disease is the leading cause of morbidity and mortality worldwide, with a substantial amount of health-care resources targeted towards its diagnosis and management. Environmental sustainability in cardiovascular care can have an important role in reducing greenhouse gas emissions and pollution and could be beneficial for improving health metrics and societal well-being and minimizing the cost of health care. In this Review, we discuss the motivations and frameworks for sustainable...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Oct 25. doi: 10.1038/s41569-024-01077-z. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Cardiovascular disease is the leading cause of morbidity and mortality worldwide, with a substantial amount of health-care resources targeted towards its diagnosis and management. Environmental sustainability in cardiovascular care can have an important role in reducing greenhouse gas emissions and pollution and could be beneficial for improving health metrics and societal well-being and minimizing the cost of health care. In this Review, we discuss the motivations and frameworks for sustainable cardiovascular care with an emphasis on the reduction of the climate-related and environmental effects of cardiovascular care. We also provide an overview of greenhouse gas emissions related to the provision of health care, including their measurement and quantification, carbon accounting, carbon disclosures and climate effects. The principles of life-cycle assessment, waste prevention and circular economics in health care are discussed, and the emissions associated with various sectors of cardiovascular care as well as the rationale for prevention as a powerful approach to reduce these emissions are presented. Finally, we highlight the challenges in environmental sustainability and future directions as applicable to cardiovascular practice.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39455886/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241029001351&v=2.18.0.post9+e462414">39455886</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01077-z>10.1038/s41569-024-01077-z</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39455886</guid>
<pubDate>Fri, 25 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Sanjay Rajagopalan</dc:creator>
<dc:creator>Scott McAlister</dc:creator>
<dc:creator>Jason Jay</dc:creator>
<dc:creator>Richard D Pham</dc:creator>
<dc:creator>Robert D Brook</dc:creator>
<dc:creator>Khurram Nasir</dc:creator>
<dc:creator>Mark J Nieuwenhuijsen</dc:creator>
<dc:creator>Philip Landrigan</dc:creator>
<dc:creator>Allegra Wiesler</dc:creator>
<dc:creator>Christina Vernon Sanborn</dc:creator>
<dc:creator>Justin R Carron</dc:creator>
<dc:creator>Kara Hammond Brooks</dc:creator>
<dc:creator>Aruni Bhatnagar</dc:creator>
<dc:creator>Sadeer Al-Kindi</dc:creator>
<dc:date>2024-10-25</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Environmental sustainability in cardiovascular practice: current challenges and future directions</dc:title>
<dc:identifier>pmid:39455886</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01077-z</dc:identifier>
</item>
<item>
<title>Method of moments framework for differential expression analysis of single-cell RNA sequencing data</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39454576/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241029001351&amp;v=2.18.0.post9+e462414
      <description>Differential expression analysis of single-cell RNA sequencing (scRNA-seq) data is central for characterizing how experimental factors affect the distribution of gene expression. However, distinguishing between biological and technical sources of cell-cell variability and assessing the statistical significance of quantitative comparisons between cell groups remain challenging. We introduce Memento, a tool for robust and efficient differential analysis of mean expression, variability, and gene...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Oct 16:S0092-8674(24)01144-9. doi: 10.1016/j.cell.2024.09.044. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Differential expression analysis of single-cell RNA sequencing (scRNA-seq) data is central for characterizing how experimental factors affect the distribution of gene expression. However, distinguishing between biological and technical sources of cell-cell variability and assessing the statistical significance of quantitative comparisons between cell groups remain challenging. We introduce Memento, a tool for robust and efficient differential analysis of mean expression, variability, and gene correlation from scRNA-seq data, scalable to millions of cells and thousands of samples. We applied Memento to 70,000 tracheal epithelial cells to identify interferon-responsive genes, 160,000 CRISPR-Cas9 perturbed T cells to reconstruct gene-regulatory networks, 1.2 million peripheral blood mononuclear cells (PBMCs) to map cell-type-specific quantitative trait loci (QTLs), and the 50-million-cell CELLxGENE Discover corpus to compare arbitrary cell groups. In all cases, Memento identified more significant and reproducible differences in mean expression compared with existing methods. It also identified differences in variability and gene correlation that suggest distinct transcriptional regulation mechanisms imparted by perturbations.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39454576/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241029001351&v=2.18.0.post9+e462414">39454576</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.09.044>10.1016/j.cell.2024.09.044</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39454576</guid>
<pubDate>Fri, 25 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Min Cheol Kim</dc:creator>
<dc:creator>Rachel Gate</dc:creator>
<dc:creator>David S Lee</dc:creator>
<dc:creator>Andrew Tolopko</dc:creator>
<dc:creator>Andrew Lu</dc:creator>
<dc:creator>Erin Gordon</dc:creator>
<dc:creator>Eric Shifrut</dc:creator>
<dc:creator>Pablo E Garcia-Nieto</dc:creator>
<dc:creator>Alexander Marson</dc:creator>
<dc:creator>Vasilis Ntranos</dc:creator>
<dc:creator>Chun Jimmie Ye</dc:creator>
<dc:date>2024-10-25</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Method of moments framework for differential expression analysis of single-cell RNA sequencing data</dc:title>
<dc:identifier>pmid:39454576</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.09.044</dc:identifier>
</item>





























</channel>
</rss>